Bryan Garnier is the leading independent European Investment Bank on Biotech Offerings
PARIS – November 13, 2006 - Bryan, Garnier & Co (“Bryan Garnier”), the independent pan-European investment bank focused on European growth companies, maintains its leading position in European Equity Capital Markets transactions for biotech companies since July 2005 according to data provided by Thomson Financial.
Bryan Garnier is the number one underwriter in value for biotech IPOs on the Euronext market. According to the Thomson Financial’s figures, the bank ranks as the number three bank when extended to the 18 different European stock markets where 33 transactions have been led and completed by all banks. Bryan Garnier completed Innate Pharma’s IPO on Euronext last week.
Pharmaceuticals and biotech have been a major focus for Bryan Garnier over the past ten years. It has a dedicated healthcare equity research team in place and benefits from longstanding relationships with the European investment community who focus on these niche sectors. Bryan Garnier’s team has recently been strengthened with the appointments of Dr François Thomas, as Head of Biotech and Antoine Flochel as Head of Pharmaceuticals.
Commenting on the bank’s leading position in these sector, Dr Thomas said, “Bryan Garnier offers fully fledged investment services to its clients in the biotech sector ranging from Private Placements and Capital Market Offerings to Corporate Finance and M&A services. These latest rankings represent a further illustration of the bank’s commitment to sponsoring highly innovative biotech companies and demonstrate our credentials in the sector.”
Gregoire Revenu, Co-Founder and Managing Director of Bryan Garnier, added, “This major achievement is the result of our dedication and focus. It demonstrates the power of our model, which combines a strong industry expertise with outstanding investment banking execution capabilities at a pan-European level.”
For more information, please contact:
Penrose Financial +
44 20 7786 4888 : Mani Pillai / Kerstin Voelkel / Stefanie Schneider
Among the 33 biotech transactions in Europe compiled from Thomson Financial databases for the last 16 months Bryan Garnier & Co ranks third in deal value to Merrill Lynch & Credit Suisse with €98,6 m raised in three deals. These deals comprise Innate Pharma and BioAlliance IPOs on Euronext and the follow-on offering on Transgène.
When enlarging the scope of our research to Biotech & Pharmaceuticals operations in Europe (excluding offerings of more than €200m) Bryan Garnier & Co ranks fifth for IPOs. This is mainly due to the strong performance of the British and Swiss offerings in biotech and biotech related deals. We excluded 3 deals that were over €200 m offerings all categorized by Thomson Financial as pharmaceutical deals (Ipsen in France, Fresenius in Germany and Grifols in Spain).